治疗后PET/CT与p16状态预测局部晚期头颈癌根治性放疗后的治疗结局
该研究回顾性分析了108例接受根治性放化疗的局部晚期头颈鳞癌患者,其中p16阳性68例(63.0%)、p16阴性40例(37.0%)。治疗后PET/CT对局部复发的阴性预测值为100%,对区域复发的阴性预测值在p16阳性患者为100%、p16阴性患者为88.5%。治疗后PET/CT与p16状态均为无复发生存的独立预测因素(p<0.01)。
要点
- 治疗后PET/CT对局部复发的阴性预测值为100%。
- 区域复发阴性预测值:p16阳性100% vs p16阴性88.5%。
- p16阴性且PET阴性患者仍有约10%区域复发风险,作者认为需更密切随访。
核心结论
- 治疗后PET/CT可预测p16阳性与p16阴性患者的治疗结局,且其预测作用独立于p16状态。
- p16阴性且PET阴性的患者存在10%的淋巴结复发风险,作者认为需更密切随访。
研究设计与样本
- 回顾性研究,纳入2008年8月1日至2015年2月28日期间接受根治性放化疗的N2A或以上期别头颈鳞癌患者108例,治疗后PET/CT在放疗后6个月内完成。
- 采用Kaplan-Meier曲线、log-rank检验和Cox比例风险回归进行统计分析。
主要发现
- 中位随访2.38年,p16阳性68例(63.0%),p16阴性40例(37.0%)。
- 2年总生存率和无复发生存率分别为93.4%和77.8%。
- PET/CT对局部复发的阴性预测值为100%;对区域复发的阴性预测值全部患者为96.5%,p16阳性患者为100%,p16阴性患者为88.5%。
- PET/CT对复发的阳性预测值全部患者为77.3%,p16阳性为50.0%,p16阴性为78.6%;对局部复发的阳性预测值全部患者为72.7%,p16阳性为50.0%,p16阴性为72.7%;对区域复发的阳性预测值全部患者为50.0%,p16阳性为33%,p16阴性为66.6%。
- 治疗后PET/CT和p16状态是无复发生存的独立预测因素(p<0.01)。
关键数值与推荐
- 治疗后PET/CT对局部复发的阴性预测值为100%。
- 区域复发阴性预测值:全部患者96.5%,p16阳性患者100%,p16阴性患者88.5%。
- 复发阳性预测值:全部患者77.3%,p16阳性患者50.0%,p16阴性患者78.6%。
- 局部复发阳性预测值:全部患者72.7%,p16阳性患者50.0%,p16阴性患者72.7%。
- 区域复发阳性预测值:全部患者50.0%,p16阳性患者33%,p16阴性患者66.6%。
临床怎么用
- 治疗后PET/CT可预测p16阳性与p16阴性患者的治疗结局,且独立于p16状态。
- 作者认为p16阴性且PET阴性的患者存在10%淋巴结复发风险,需更密切随访。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To retrospectively review post-treatment (post-tx) FDG-PET/CT scans in patients with advanced head and neck squamous cell carcinoma (HNSCC) and known p16 status, treated with definitive (chemo)radiation (RT). METHODS: A total of 108 eligible patients had N2A or greater HNSCC treated with chemoRT from August 1, 2008, to February 28, 2015, with post-tx PET/CT within 6 months after RT. Kaplan-Meier curves, log-rank statistics, and Cox proportional hazards regression were used for statistical analysis. RESULTS: Median follow-up was 2.38 years. Sixty-eight (63.0%) patients had p16+ and 40 (37.0%) had p16- status. Two-year overall survival and recurrence-free survival were 93.4% and 77.8%, respectively. The negative predictive value (NPV) of PET/CT for local recurrence (LR) was 100%. The NPV for regional recurrence (RR) was 96.5% for all patients, 100% for p16+ patients, and 88.5% for p16- patients. The positive predictive value (PPV) of PET/CT for recurrence was 77.3% for all patients, 50.0% for p16+, and 78.6% for p16-. The PPV for LR was 72.7% for all patients, 50.0% for p16+ patients, and 72.7% for p16- patients. The PPV for RR was 50.0% for all patients, 33% for p16+, and 66.6% for p16-. Post-tx PET/CT and p16 status were independent predictors of recurrence-free survival (p < 0.01). CONCLUSIONS: Post-tx PET/CT predicts treatment outcomes in both p16 + and p16- patients, and does so independently of p16 status. P16- patients with negative PET have a 10% risk of nodal recurrence, and closer follow-up in these patients is warranted.
引用
- Awan MJ, Lavertu P, Zender C, et al. Post-treatment PET/CT and p16 status for predicting treatment outcomes in locally advanced head and neck cancer after definitive radiation. Eur J Nucl Med Mol Imaging. 2017. PMID: 28091733. doi:10.1007/s00259-016-3612-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。